Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
10.22
+0.14 (1.39%)
Nov 28, 2025, 4:00 PM EST - Market closed
Entrada Therapeutics Revenue
Entrada Therapeutics had revenue of $1.61M in the quarter ending September 30, 2025, a decrease of -91.75%. This brings the company's revenue in the last twelve months to $61.52M, down -71.42% year-over-year. In the year 2024, Entrada Therapeutics had annual revenue of $210.78M with 63.38% growth.
Revenue (ttm)
$61.52M
Revenue Growth
-71.42%
P/S Ratio
6.88
Revenue / Employee
$336,175
Employees
183
Market Cap
368.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 210.78M | 81.77M | 63.38% |
| Dec 31, 2023 | 129.01M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TRDA News
- 11 days ago - Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts - Seeking Alpha
- 22 days ago - Entrada Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Entrada Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Entrada Therapeutics, Inc. - Special Call - Seeking Alpha
- 3 months ago - Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program - GlobeNewsWire
- 3 months ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
- 4 months ago - Entrada Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire